Table 1 Baseline demographics and characteristics of patients from the double-blind, placebo-controlled and cumulative periods
Double-blind, placebo*-controlled period | Cumulative period | ||
|---|---|---|---|
Abatacept (N = 2653) | Placebo (N = 1485) | Abatacept (N = 7044) | |
Patient demographics | |||
Age, years | 51.7 (12.4) | 51.4 (12.3) | 51.5 (12.6) |
Weight, kg | 73.5 (18.8) n = 2650 | 73.8 (18.6) n = 1484 | 74.4 (19.0) n = 7036 |
Female, n (%) | 2099 (79.1) | 1184 (79.7) | 5675 (80.6) |
White, n (%) | 2283 (86.1) | 1285 (86.5) | 5940 (84.3) |
Durations of exposure, months | 10.8 (3.3) | 10.3 (3.5) | 36.9 (26.2) |
Disease characteristics | |||
Disease duration, years | 8.1 (8.5) n = 2577 | 7.5 (8.5) n = 1439 | 8.1 (8.6) n = 6933 |
hsCRP, mg/L | 26.3 (29.8) n = 2567 | 27.2 (33.5) n = 1435 | 24.8 (29.8) n = 6936 |
Tender joint count (28) | 29.8 (13.9) n = 1618 | 29.9 (13.8) n = 960 | 28.9 (14.2) n = 4545 |
Swollen joint count (28) | 20.9 (10.2) n = 1618 | 20.9 (9.8) n = 960 | 19.8 (9.9) n = 4545 |
HAQ-DI | 1.5 (0.7) n = 2559 | 1.6 (0.7) n = 1427 | 1.6 (0.7) n = 6895 |
Patient pain (0–100 VAS)† | 63.4 (21.0) n = 2212 | 63.4 (21.1) n = 1173 | 64.3 (21.1) n = 5514 |
Concomitant medications‡ | |||
NSAIDs, n (%) | 2238 (84.4) | 1269 (85.5) | 5668 (80.5) |
Oral glucocorticoids, n (%) | 1499 (56.5) | 823 (55.4) | 4285 (60.8) |
Oral dose, mg | 7.5 (8.1) | 9.1 (9.1) | 12.3 (162.5) |
MTX, n (%) | 1809 (68.2) | 948 (63.8) | 5184 (73.6) |
Anti-TNF, n (%) | 169 (6.4) | 82 (5.5) | 262 (3.7) |